2023-07-07 17:35:14
The centenary Osório de Moraes Laboratories, known throughout the national territory for products such as Auris-Sedina and Imescard Pills, was acquired by a group of investors from Minas Gerais, led by businessman Antônio Carlos Vargas. The value of the purchase transaction was not disclosed, but the expectation is that there will be an investment of over R$ 300 million over the next five years. The first step towards the expansion of the industry is already happening and do not think small. Laboratorios Osório de Moraes invests in the prevention and treatment of hair loss. The industry is nationally producing and commercializing an anti-hair loss formulation, the result of more than 20 years of clinical studies at UFMG, with the use of genetic engineering.
A well-known name in the scenario of the Brazilian pharmaceutical industry, Vargas has already worked at Laboratorio Teuto Brasileiro and was the founder of Pharlab Indústria Farmacêutica S/A. Born in the city of Lagoa da Prata, in Minas Gerais, the businessman explains that entering the anti-hair loss technological innovation segment is strategic, as the sector is booming in Brazil. “It is one of the fastest growing areas in the national market. We unite science, technology and the credibility of more than 100 years of Laboratorios Osório de Moraes, with a unique distribution capacity”, evaluates Vargas.
Meeting in Sao Paulo
On Friday, July 7th, the scientists who were at the forefront of the scientific studies that resulted in the development of the anti-hair loss solution, will be in São Paulo (capital), at the headquarters of the ISMD faculty (Instituto Superior de Medicina), in Vila Mariana, for a chat with around 100 dermatologists for a breakdown of the research.
About the formulation developed by UFMG
Called ENDCALVE, the formula is the result of over 20 years of scientific studies and clinical trials. The research was developed by a group of scientists from the National Institute of Science and Technology in Nanobiopharmaceuticals (INCT NanoBiofar), using innovative constituents, enabling preservation and follicular stimulation, proven in experiments involving genetic engineering.
UFMG recently received from the National Institute of Intellectual Property (INPI), the definitive registration of the patent for its hair loss formulation. The Registered Patent, which gives the right to the manufacture, distribution and commercial exploitation of the product, was licensed by UFMG to “Laboratório Osório de Moraes”, a company founded 101 years ago, with an industrial park located in Contagem, and with commercial operations throughout the territory national.
According to UFMG scientist Ana Paula Corrêa Oliveira Bahia, what differentiates this formulation from the others available on the market is the combined therapy technique, enabling the full use of biocompatible active principles with the penetration power of nanoencapsulation. The liposome used in the formula has great affinity with the hair follicle, favoring the local release of high-performance components, an exclusive property of this formulation.
She also details that the technology is innovative because it inaugurates a treatment concept that combines the power of its biocompatible constituents (follicular metabolism accelerators) – responsible for stimulating the bulb, available directly in the hair follicle – once morest the high penetration power of the nanoencapsulated particles, “nanotechnological components” (particles with dimensions smaller than 100 nanometers)”, ensuring the high efficacy of the treatment. The solution was developed with the aim of promoting the recovery of the hair bulb, ensuring the stability and real bioavailability of bioidentical active principles.
Free from side effects
The scientist reports that scientific studies have indicated that topical use of the formulation does not cause the feared side effects commonly seen in other formulations and/or treatments for Alopecia, such as erectile dysfunction, localized skin irritation, allergies and photosensitivity, resulting in high dermatological safety in the its use: “The absence of side effects is due to the mechanism of action that uses biocompatible constituents, that is, components produced by the body itself, without foreign substances like the others, and without interaction with the bloodstream”.
The product is effective in people who still have the hair follicle, because that is where the action of the formulation is focused, people who are losing hair, men and women, who still have the follicle can benefit from the technology.
1689010711
#Osório #Moraes #invests #hair #loss #segment